Simple blood test could decide best therapy for advanced lung cancer
NCT ID NCT05715229
First seen Jan 22, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This phase 2 trial tests whether a blood test that tracks tumor DNA can guide treatment for people with advanced non-small cell lung cancer. Participants will receive either immunotherapy alone or immunotherapy plus chemotherapy, based on their blood test results. The goal is to see if this personalized approach improves how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jersey Shore University Medical Center
NOT_YET_RECRUITINGNeptune City, New Jersey, 07753, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
John Theurer Cancer Center, Hackensack Meridian Health
RECRUITINGHackensack, New Jersey, 07410, United States
Contact Phone: •••-•••-••••
-
Lombardi Comprehensive Cancer Center, Georgetown University
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20007, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab (Opdivo), Ipilimumab (Yervoy), Carboplatin, Paclitaxel, Pemetrexed
What this could lead to
If successful, this could help doctors personalize treatment for advanced lung cancer, using a simple blood test to decide who needs only immunotherapy and who needs added chemotherapy.
What could go wrong
This is a phase 2 trial with only 108 participants, so results are preliminary. The blood test may not reliably predict treatment response, and immunotherapy can cause serious immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.